{"id":696,"date":"2024-01-17T13:36:40","date_gmt":"2024-01-17T13:36:40","guid":{"rendered":"https:\/\/www.agb-pharma.com\/?page_id=696"},"modified":"2024-11-15T12:29:47","modified_gmt":"2024-11-15T12:29:47","slug":"pharmacovigilance-policy","status":"publish","type":"page","link":"https:\/\/www.agb-pharma.com\/se-eng\/pharmacovigilance-policy\/","title":{"rendered":"Pharmacovigilance Policy"},"content":{"rendered":"\n\n\t\t\t\t\"agb_logo_green\"\n\t\t\t\t<\/a>\n\t\t\t\t\t\t
SWEDEN – ENG<\/h5>\n\t\t\t

SWEDEN<\/a>
UK<\/a>
NORWAY<\/a>
DENMARK<\/a><\/p>\n\t\t\t\t\"border2\"\n

\n\t\tPharma\u00adcovigilance policy\n\t<\/h1>\n\t

The purpose of this Pharmacovigilance policy is to describe how AGB-Pharma AB (”AGB”, ”we”, ”our” or ”us”) collect and process personal data in order to fulfil our obligation to monitor the safety of the products we develop and market (”Pharmacovigilance Obligation”).<\/p>\n

All personal data collected in order to fulfil this Pharmacovigilance Obligation is processed in accordance with the UK Data Protection Act 2018, and solely to the extent that it is relevant to and necessary for the fulfilment of our Pharmacovigilance Obligation.<\/p>\n

For further information on how we process personal data in other contexts, see our Personal Data Policy<\/a>.<\/p>\n

Product safety and personal data<\/h3>\n

Product safety is important to us. Different forms of side effects or adverse events associated with the use of a pharmaceutical product can differ and it may not, therefore, always be possible to detect them during the clinical development of the products. It is consequently of the utmost importance that we are able to catch all side effects, whether common or uncommon, so that we can monitor the safety of the products, protect public health, and ensure a high standard of quality. The Pharmacovigilance Obligation exists to enable regulatory authorities (MHRA and other authorities) and us to follow up on and address side effects and adverse events, and to work to prevent similar side effects occurring in future.<\/p>\n

The Pharmacovigilance Obligation means that AGB-Pharma has a legal obligation to collect certain personal data from people who use our pharmaceutical products. The types of personal data that we collect and process are shown below.<\/p>\n

Which personal data do we process?<\/h3>\n

We may collect and process the following types of personal data when you, your doctor, or another third party submits information to us regarding a side effect experienced in conjunction with the use of AGB-Pharma’s products.<\/p>\n

Personal data about the person reporting a side effect:<\/em><\/p>\n